Huntleigh Advisors Inc. bought a new stake in InspireMD, Inc. (NYSE:NSPR - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 117,407 shares of the company's stock, valued at approximately $316,000. Huntleigh Advisors Inc. owned 0.38% of InspireMD at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Uniting Wealth Partners LLC acquired a new position in shares of InspireMD during the first quarter valued at $27,000. Renaissance Technologies LLC acquired a new position in InspireMD during the 4th quarter valued at about $27,000. Schonfeld Strategic Advisors LLC increased its stake in InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after buying an additional 18,233 shares during the period. Courier Capital LLC acquired a new position in InspireMD during the 1st quarter valued at about $81,000. Finally, Northern Trust Corp increased its stake in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after buying an additional 24,452 shares during the period. 44.78% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on NSPR shares. Wall Street Zen started coverage on shares of InspireMD in a research note on Monday, May 5th. They set a "sell" rating on the stock. Piper Sandler lowered their price target on InspireMD from $4.50 to $4.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th.
Get Our Latest Stock Analysis on InspireMD
InspireMD Trading Down 0.9%
NYSE:NSPR traded down $0.02 during mid-day trading on Monday, reaching $2.22. 212,000 shares of the stock were exchanged, compared to its average volume of 67,358. The business has a fifty day moving average price of $2.43 and a 200 day moving average price of $2.65. The firm has a market capitalization of $68.01 million, a PE ratio of -2.96 and a beta of 0.57. InspireMD, Inc. has a 1-year low of $1.99 and a 1-year high of $3.80.
InspireMD Profile
(
Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
See Also

Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.